These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 18819053)

  • 1. Contrasting effects of eplerenone and spironolactone on adrenal cell steroidogenesis.
    Ye P; Yamashita T; Pollock DM; Sasano H; Rainey WE
    Horm Metab Res; 2009 Jan; 41(1):35-9. PubMed ID: 18819053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
    Arai K; Homma T; Morikawa Y; Ubukata N; Tsuruoka H; Aoki K; Ishikawa H; Mizuno M; Sada T
    Eur J Pharmacol; 2015 Aug; 761():226-34. PubMed ID: 26073023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eplerenone inhibits the intracrine and extracellular actions of angiotensin II on the inward calcium current in the failing heart. On the presence of an intracrine renin angiotensin aldosterone system.
    De Mello WC; Gerena Y
    Regul Pept; 2008 Nov; 151(1-3):54-60. PubMed ID: 18585409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis.
    Sica DA
    Heart Fail Rev; 2005 Jan; 10(1):23-9. PubMed ID: 15947888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralocorticoid receptor antagonist.
    Takeda Y
    Hypertens Res; 2004 Nov; 27(11):781-9. PubMed ID: 15824460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.
    Hu X; Li S; McMahon EG; Lala DS; Rudolph AE
    Mini Rev Med Chem; 2005 Aug; 5(8):709-18. PubMed ID: 16101407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mineralocorticoid receptor antagonists, a class beyond spironolactone--Focus on the special pharmacologic properties of eplerenone.
    Seferovic PM; Pelliccia F; Zivkovic I; Ristic A; Lalic N; Seferovic J; Simeunovic D; Milinkovic I; Rosano G
    Int J Cardiol; 2015 Dec; 200():3-7. PubMed ID: 26404746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eplerenone mimics features of the alternative activation in macrophages obtained from patients with heart failure and healthy volunteers.
    Łabuzek K; Liber S; Bułdak Ł; Krupej-Kędzierska J; Machnik G; Bobrzyk M; Okopień B
    Eur J Pharmacol; 2014 Mar; 726():96-108. PubMed ID: 24486397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin and mineralocorticoid receptor antagonism attenuates cardiac oxidative stress in angiotensin II-infused rats.
    Minas JN; Thorwald MA; Conte D; Vázquez-Medina JP; Nishiyama A; Ortiz RM
    Clin Exp Pharmacol Physiol; 2015 Nov; 42(11):1178-88. PubMed ID: 26234762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eplerenone: a selective aldosterone receptor antagonist (SARA).
    Delyani JA; Rocha R; Cook CS; Tobert DS; Levin S; Roniker B; Workman DL; Sing YL; Whelihan B
    Cardiovasc Drug Rev; 2001; 19(3):185-200. PubMed ID: 11607037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biotransformation of the mineralocorticoid receptor antagonists spironolactone and canrenone by human CYP11B1 and CYP11B2: Characterization of the products and their influence on mineralocorticoid receptor transactivation.
    Schiffer L; Müller AR; Hobler A; Brixius-Anderko S; Zapp J; Hannemann F; Bernhardt R
    J Steroid Biochem Mol Biol; 2016 Oct; 163():68-76. PubMed ID: 27125452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor.
    Rogerson FM; Yao Y; Smith BJ; Fuller PJ
    Clin Exp Pharmacol Physiol; 2004 Oct; 31(10):704-9. PubMed ID: 15554912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1.
    Amazit L; Le Billan F; Kolkhof P; Lamribet K; Viengchareun S; Fay MR; Khan JA; Hillisch A; Lombès M; Rafestin-Oblin ME; Fagart J
    J Biol Chem; 2015 Sep; 290(36):21876-89. PubMed ID: 26203193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eplerenone for the treatment of cardiovascular disorders.
    Watanabe M; Krum H
    Expert Rev Cardiovasc Ther; 2012 Jul; 10(7):831-8. PubMed ID: 22908915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldosterone receptor antagonists and cardiovascular disease: do we need a change of the guard?
    Jewell CW; Watson LE; Mock J; Dostal DE
    Cardiovasc Hematol Agents Med Chem; 2006 Apr; 4(2):129-53. PubMed ID: 16611048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of brain corticosterone and aldosterone in central angiotensin II-induced hypertension.
    Huang BS; White RA; Ahmad M; Leenen FH
    Hypertension; 2013 Sep; 62(3):564-71. PubMed ID: 23856493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eplerenone: a new selective aldosterone receptor antagonist.
    Weinberger MH
    Drugs Today (Barc); 2004 Jun; 40(6):481-5. PubMed ID: 15349128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-genomic effects of spironolactone and eplerenone in cardiomyocytes of neonatal Wistar rats: do they evoke cardioprotective pathways?
    Hermidorff MM; Faria Gde O; Amâncio Gde C; de Assis LV; Isoldi MC
    Biochem Cell Biol; 2015 Feb; 93(1):83-93. PubMed ID: 25488178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
    Lainscak M; Pelliccia F; Rosano G; Vitale C; Schiariti M; Greco C; Speziale G; Gaudio C
    Int J Cardiol; 2015 Dec; 200():25-9. PubMed ID: 26404748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.